Speciality: Hematology
Description:
A warm welcome to all the medical professionals in this memorable scientific session of thromboprophylaxis in medical settings. We have Dr. Ashish Bhalla, Dr. Tobias Tritschler and Dr. Bharat Jagiasi to lead this session.
The primary subject of discussion in this webinar is the increasing risk of hospital acquired deep vein thrombosis and pulmonary embolism among the patients. Get a broader knowledge of the above mentioned topics by learning about different instances.
Venous thromboembolism is the most common cause of death observed in surgical patients. Thromboprophylaxis is the mechanical method to promote venous outflow from the legs and antithrombotic drugs. This can be an effective means of reducing morbidity and mortality in the patients with hospital acquired deep vein thrombosis.
Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Journal Club: A well-accepted and safe method for soft tissue sarcoma biopsy.
2.
ASCO: Vepdegestrant ups survival in ER+, HER2− advanced breast cancer with ESR1 mutations
3.
'Cell-in-cell' mechanism explains how blood cancer uses bone marrow to evade treatment
4.
Black women are more likely to die of breast cancer. Close the gap by looking into mammogram studies.
5.
Reduced Suicide Rates in Cancer Patients; Enhanced Circadian Rhythm; HIV Vaccine for Cancer Patients?
1.
Unlocking the Potential of Talquetamab: A Revolutionary Approach to Cancer Treatment
2.
Breakthroughs in Oncology: Advances in Immunotherapy, Radiation & Precision Diagnostics
3.
Radiomics-Based Prediction of Treatment Response in Cancer
4.
Predicting Incidental Prostate Cancer in BPH Surgery Patients
5.
Liquid Biopsies Unveiling the Future of Precision Cancer Management by 2025
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
3.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
4.
Navigating the Complexities of Ph Negative ALL - Part VI
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation